Contineum MS drug stumbles in mid-stage trial
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Desai is currently serving the company as Group Finance Controller
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The partnership will enable rapid and reliable product delivery
Winlevi is authorized in EU for the treatment of acne vulgaris
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
Subscribe To Our Newsletter & Stay Updated